Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ThisCART19A in r/r B-cell Lymphoma
NCT05535673Phase 1Unknown
- Sponsor
- Zhengzhou University
- Start
- Sep 2022
- Primary completion
- Jul 2025
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
01
Overview
Phase 1, open-label, single-arm trial of thiscart19a in B cell lymphoma, sponsored by Zhengzhou University. Primary endpoints: Dose Limiting Toxicity at 28 days, Treatment Emergent Adverse Events at 2 years and 1 more. Status: unknown.
02
Drugs
thiscart19a
03
Conditions
B cell lymphoma
Beyond the preview
Go deeper on NCT05535673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05535673.